CALL - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 02:00:12 2024-07-11 pm EDT | ||
| 17.65 EUR | +0.63% |
|
| Current month | +7.82% | ||
| 1 month | +3.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 17.65 | +0.63% |
| 24-07-10 | 17.54 | +2.10% |
| 24-07-09 | 17.18 | +3.06% |
| 24-07-08 | 16.67 | +3.09% |
| 24-07-05 | 16.17 | +2.47% |
Delayed Quote Deutsche Boerse AG
Last update July 11, 2024 at 02:00 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VU8GEQ |
| ISIN | DE000VU8GEQ6 |
| Date issued | 2023-06-13 |
| Strike | 303.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.65 € |
|---|---|
| Lowest since issue | 5.34 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
492.1
USD
Average target price
473.1
USD
Spread / Average Target
-3.87%
- Stock Market
- Certificates
- Certificat
